K
Kyverna
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases
About Kyverna
Kyverna Therapeutics is a biotech startup that operates in the healthcare sector, specifically in the field of autoimmune disease treatment. The company is focused on developing innovative cell therapies that can potentially cure autoimmune diseases. Their primary clients are patients suffering from autoimmune diseases, a market that is continually growing due to the increasing prevalence of these conditions.
Read full description
Kyverna's business model revolves around the use of synthetic biology, immunology, and cell engineering to create a new class of T cell therapies. These therapies are designed to target and modulate the underlying causes of autoimmunity. Unlike traditional treatments that require chronic dosing, Kyverna's cell therapy aims to control the disease optimally and long-lastingly through a single infusion. This approach could potentially revolutionize the treatment of autoimmune diseases, providing a more effective and convenient solution for patients.
The company also seeks to expand its technology and capabilities through in-licensing and collaboration opportunities. This strategy allows Kyverna to stay at the forefront of cell therapy innovation and ensure its therapies are as effective and advanced as possible.
In terms of revenue, Kyverna makes money by developing and selling its cell therapies to patients and healthcare providers. The company's potential for growth and profitability is significant, given the high demand for effective treatments for autoimmune diseases.
At a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- Emeryville, United States
- Listing
- IPO 2024
- Employees
- 165
- Open positions
- 16
- Dealroom signal
- 85.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Autoimmune, Immune System, Synthetic Biology, Spinout, Biotech and Pharma, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Oct 2025 | $0 | — | Oxford Finance | ↗ |
| IPOOther financing | Feb 2024 | $319M | $319M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$177M | — |
| 2025 | $0 | — | −$159M | — |
| 2024 | $0 | — | −$125M | — |
| 2023 | $0 | -100% | −$58M | — |
| 2022 | $7M | +24.2% | −$28M | -395.4% |
| 2021 | $5.7M | — | −$26M | -455.5% |
Growth signals
Latest recorded traffic for Kyverna is 14K monthly website visits, down 12.5% over the last three months. Kyverna's team grew 13% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A15 investors entered at this stage
Vida Ventures
Westlake Village BioPartners
Northpond Ventures
Hudson Bay Capital Management
Argentum Group- JCjVen Capital
Intellia Therapeutics
Gilead Sciences
LYFE Capital- HPHealthCor Partners
CAM Capital
Insight Partners
RTW Investments
Bain Capital Life Sciences
GordonMD Global Investment
Series B and later1 investor entered at this stage
Oxford Finance
Other known investors1 additional known investor
National Institutes of Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kyverna on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kyverna’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.